AU768911B2 - Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation - Google Patents

Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation Download PDF

Info

Publication number
AU768911B2
AU768911B2 AU34517/00A AU3451700A AU768911B2 AU 768911 B2 AU768911 B2 AU 768911B2 AU 34517/00 A AU34517/00 A AU 34517/00A AU 3451700 A AU3451700 A AU 3451700A AU 768911 B2 AU768911 B2 AU 768911B2
Authority
AU
Australia
Prior art keywords
cyclic
cgp
disorders
diseases
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34517/00A
Other languages
English (en)
Other versions
AU3451700A (en
Inventor
Meir Shinitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU3451700A publication Critical patent/AU3451700A/en
Application granted granted Critical
Publication of AU768911B2 publication Critical patent/AU768911B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU34517/00A 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation Ceased AU768911B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation
IL129178 1999-03-25
PCT/IL2000/000185 WO2000057865A2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation

Publications (2)

Publication Number Publication Date
AU3451700A AU3451700A (en) 2000-10-16
AU768911B2 true AU768911B2 (en) 2004-01-08

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34517/00A Ceased AU768911B2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation

Country Status (16)

Country Link
US (1) US6914056B1 (enExample)
EP (1) EP1162959B1 (enExample)
JP (1) JP2002540146A (enExample)
KR (1) KR20010112364A (enExample)
CN (1) CN1348375A (enExample)
AT (1) ATE290385T1 (enExample)
AU (1) AU768911B2 (enExample)
BR (1) BR0009296A (enExample)
CA (1) CA2368597A1 (enExample)
DE (1) DE60018554T2 (enExample)
HK (1) HK1042038A1 (enExample)
IL (1) IL129178A0 (enExample)
MX (1) MXPA01009650A (enExample)
NZ (1) NZ514525A (enExample)
RU (1) RU2247557C2 (enExample)
WO (1) WO2000057865A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
US8101552B2 (en) * 2005-03-14 2012-01-24 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
ES2518371T3 (es) * 2006-04-26 2014-11-05 Toyama Chemical Co., Ltd. Inductor de la neurogénesis o agente terapéutico para la neuropatía que comprende un derivado de éter alquílico o una sal del mismo
KR20090097943A (ko) * 2006-12-28 2009-09-16 오짜노미즈 유니버시티 환상 포스파티딘산 유도체를 포함하는 진통제
EP2389348B1 (en) * 2009-01-09 2017-11-15 Sigma-Aldrich Co. LLC Process for the synthesis of beta glycerol phosphate
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
WO2014115885A1 (ja) 2013-01-28 2014-07-31 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
EP3386995A1 (en) * 2015-12-08 2018-10-17 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center １−ｏ−アシルグリセロール２，３−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素ｃの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Also Published As

Publication number Publication date
RU2247557C2 (ru) 2005-03-10
AU3451700A (en) 2000-10-16
WO2000057865A9 (en) 2001-11-15
CN1348375A (zh) 2002-05-08
EP1162959B1 (en) 2005-03-09
NZ514525A (en) 2003-10-31
MXPA01009650A (es) 2002-07-02
WO2000057865A3 (en) 2001-06-28
JP2002540146A (ja) 2002-11-26
BR0009296A (pt) 2001-12-18
HK1042038A1 (zh) 2002-08-02
DE60018554D1 (de) 2005-04-14
US6914056B1 (en) 2005-07-05
WO2000057865A2 (en) 2000-10-05
CA2368597A1 (en) 2000-10-05
EP1162959A2 (en) 2001-12-19
KR20010112364A (ko) 2001-12-20
ATE290385T1 (de) 2005-03-15
IL129178A0 (en) 2000-02-17
DE60018554T2 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
EP1162959B1 (en) Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
Bielefeldt et al. Phosphorylation and dephosphorylation modulate a Ca (2+)‐activated K+ channel in rat peptidergic nerve terminals.
Soubrié et al. Chlordiazepoxide reduces in vivo serotonin release in the basal ganglia of encéphale isolé but not anesthetized cats: evidence for a dorsal raphe site of action.
Morrisett et al. Biochemical evidence for enhanced sensitivity to N-methyl-D-aspartate in the hippocampal formation of kindled rats
CA2162232C (en) Cerebration improver
CN1972697A (zh) 治疗发作和发作性疾病的化合物和方法
HU193302B (en) Process for producing phospholipide compositions and pharmaceutical compositions containing them as active agents
Johnston et al. GABA receptors and phospholipids
US8017597B2 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
Dixon et al. Lithium enhances accumulation of [3H] inositol radioactivity and mass of second messenger inositol 1, 4, 5‐trisphosphate in monkey cerebral cortex slices
JP2002514185A (ja) ＮＡＡＬＡＤａｓｅ阻害剤を用いる強迫性障害の治療の医薬組成物及び方法
Osborne et al. Memantine stimulates inositol phosphates production in neurones and nullifies N-methyl-D-aspartate-induced destruction of retinal neurones
WO1998026786A1 (en) Caged membrane-permeant inositol phosphates
DE69624121T2 (de) Membranen possierende second messengers
WO1994023724A1 (en) Membrane-permeant second messengers
AU776502B2 (en) Cyclic glycerophosphates and analogs thereof
Sourkes et al. Serotonin and dopamine in the extrapyramidal system
NZ513565A (en) Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
Strunecka et al. What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us?
Donoso et al. Nanomolar clodronate induces adenosine accumulation in the perfused rat mesenteric bed and mesentery-derived endothelial cells
US20060040901A1 (en) Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants
HONGO et al. Effects of various drugs and extrinsic denervation on the non-adrenergic inhibitory neurons in the rat stomach
Briant Actions of Drugs on Metabolic Processes in the Central Nervous System
SWIFT STUDIES ON THE ORGANIZATION AND FUNCTION OF THE GAMMA-AMINOBUTYRIC ACID SYSTEM IN THE STRIATUM AND SUBSTANTIA NIGRA OF THE RAT BRAIN.

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)